SOUTH SAN FRANCISCO, Calif.,
Sept. 9, 2020 /PRNewswire/
-- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that
Dean Schorno, the company's chief
financial officer, is scheduled to present a company overview at
two virtual investor conferences in September.
Investor Presentations:
H.C. Wainwright
22nd Annual Global Investment
Conference
Date: Tuesday,
September 15, 2020
Time: 1:00pm ET/10:00am PT
Cantor Fitzgerald Virtual Global Healthcare Conference
2020
Date: Wednesday,
September 16, 2020
Time: 1:20pm ET/10:20am PT
To access these events live or the archived webcasts, go to the
Investors section of the company's website at www.rigel.com. Please
connect to Rigel's website several minutes prior to the start of
the live webcast to ensure adequate time for any software download
that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate) tablets,
the only oral spleen tyrosine kinase (SYK) inhibitor, for the
treatment of adult patients with chronic immune thrombocytopenia
who have had an insufficient response to a previous treatment. The
product has been approved by the European Commission for the
treatment of chronic immune thrombocytopenia in adult patients who
are refractory to other treatments and is marketed in Europe under the name TAVLESSE®
(fostamatinib). Fostamatinib is currently being studied in an
investigator-sponsored trial conducted by Imperial College London
for the treatment of COVID-19
pneumonia1.
Rigel's clinical programs include a Phase 3 study of
fostamatinib in warm autoimmune hemolytic anemia (AIHA); a
completed Phase 1 study of R8351, a
proprietary molecule from its interleukin receptor associated
kinase (IRAK) inhibitor program; and an ongoing Phase 1 study of
R5521, a proprietary molecule from its
receptor-interacting protein kinase (RIP) inhibitor program. In
addition, Rigel has product candidates in clinical development with
partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1The product for this use or indication
is investigational and has not been proven safe or effective by any
regulatory authority.
IR Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-two-upcoming-investor-conferences-301126011.html
SOURCE Rigel Pharmaceuticals, Inc.